APLCC AND ITMIG JOINT SESSIONS MONDAY, NOVEMBER 26  by unknown
APLCC/ITMIG 2012 Abstracts  Volume 7, Number 11, Supplement 5, November 2012
Copyright © 2012 BY THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER S432 
APLCC AND ITMIG JOINT SESSIONS –  
MONDAY, NOVEMBER 26 
  EXPAND YOUR THINKING LECTURE -  
  November 26, 2012 13:30-15:00
EXPAND YOUR THINKING LECTURE - November 26, 2012 13:30-15:00
BIOSTATISTICS TOWARDS BETTER COMMUNICATION  
BETWEEN CLINICIANS AND STATISTICIANS
Kenichi Yoshimura  
Kyoto University Hospital, Kyoto/JAPAN
With the increasing complexity of clinical trial design and analysis, a greater level of 
knowledge and expertise is required not only for clinicians, but also for statisticians 
involved in clinical trials. In this talk, I focus on statistical issues, which we faced in 
recent clinical trials. The first topic is interim analysis, statistical analysis of the trial 
data, summarized by treatment arm, undertaken before the planned formal analysis at 
the end of the trial. Although early stopping may be seen to confer benefits for patients 
allocated the apparently poorer treatment, the results may be incorrect owing to random 
highs and lows, sometime very impressive ones, with small sample sizes and be less 
persuasive than they would be after continuing the trial. Recent trials, CALGB9633 
etc., are used to illustrate the statistical issues of interim analysis. Preliminary results of 
CALGB 9633 were reported at ASCO 2004 (median follow-up, 34 months), and the trial 
was terminated early by the data safety monitoring committee because of a significant 
overall survival (OS) benefit seen in the adjuvant chemotherapy arm (HR 0.62, 95%CI 
0.41-0.95, p=0.028). The adjuvant chemotherapy became standard of care on the basis 
of this report. However, the positive findings were short-lived. Subsequent updated 
analysis, presented at ASCO 2006 (median follow-up, 54 months), no longer showed 
a significant OS benefit (HR 0.80, 95% CI 0.60-1.07, p=0.10). Clinicians, researchers 
and patients had to struggle with how best to interpret the inconsistent results. The 
second topic is the design of non-inferiority trials. Non-inferiority trials are designed to 
demonstrate that a treatment is not worse than a comparator, usually an active control, 
by more than a pre-specified, small amount. This amount is known as the non-inferiority 
margin. In order to demonstrate non-inferiority, the widely recommended approach is 
to pre-specify a non-inferiority margin in the protocol and take it into account in the 
sample size determination. A recent trial, FACT study, is used to illustrate the issues 
of design and interpretation in non-inferiority trials. Better communication between 
clinicians and statisticians is neede for further efficient advancement of knowledge and 
understanding of qualitative aspect of medicine.
Keywords: clinician-statistician interaction, Statistical methodology, Interim analysis, 
non-inferiority trial
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BAYESIAN STATISTICS IN CLINICAL RESEARCH
J Jack Lee  
Biostatistics, University Of Texas MD Anderson Cancer Center, Houston, Texas/
UNITED STATES OF AMERICA
Statistics is a science of quantitative reasoning. It provides a framework for assessing 
information contained in the data in the midst of uncertainty. Statistics is used to 
quantify the probability of an event so that a proper inference can be made in theerves 
evidence-based medicine. There are two main approaches for statistical inference: 
the predominant frequentist approach and the lesser known Bayesian approach. In 
this “Expand Your Thinking Lecture,” these two approaches will be compared and 
contrasted, with special emphasis on the development and use of Bayesian statistics. 
Learning statistics can help sharpen quantitative reasoning skills. As a result, more 
efficient clinical trials can be designed and more accurate inference can be attained 
to advance knowledge in clinical research. Although the famous Bayes theorem 
developed by Reverend Thomas Bayes was published posthumously in 1763 — long 
before frequentist methods became popular — the Bayesian method has historically 
been underutilized and underappreciated compared to its frequentist counterpart. The 
Bayesian method treats an unknown parameter (e.g., the real treatment effect) as random 
and the known data as fixed. The Bayesian approach calculates the probability of the 
parameters given the data; whereas the frequentist approach computes the probability 
of the data given the parameters. Hence, these two methods are complementary. How 
does the Bayesian method work? Simply put, the Bayesian method follows these three 
steps: (1) obtain a prior distribution of the parameter of interest; (2) compute the data 
likelihood; and (3) synthesize these two pieces of information to form a posterior 
distribution. The posterior distribution then becomes the prior distribution for the 
subsequent evaluation. Some unique strengths of the Bayesian approach are as follows: 
(i) Compared to the frequentist approach, the Bayesian approach is more intuitive and 
addresses the problem at hand directly. For example, it can calculate the probability 
that the null hypothesis is true. On the other hand, the frequentist approach calculates 
the probability of the data given that the null hypothesis is true (e.g., the P value), which 
provides an indirect way to assess whether the null hypothesis is true. (ii) The Bayesian 
approach models the unknown parameter with a distribution and properly addresses 
various levels of uncertainty. For example, a hierarchical Bayes model can be constructed 
to evaluate the response rate of a drug in subgroups of patients and/or in multi-center 
trials. (iii) The Bayesian method accommodates more frequent monitoring and interim 
decision making during a trial; thus, it provides a platform for sequential learning. The 
prior distribution is updated by the data to form the posterior distribution. The resulting 
posterior distribution then becomes the prior distribution for a future evaluation. Most 
clinical trials are conducted over an extended period of time. Hence, it is desirable to 
frequently monitor the interim results so decisions can be made early when sufficient 
evidence has accumulated. (iv) The Bayesian method takes the “learn as you go” 
approach. The built-in “learning” feature makes the Bayesian approach adaptive in 
nature. The conduct of a clinical trial can be adapted according to the knowledge gained 
from the currently observed data. For example, a trial design that incorporates outcome-
adaptive randomization can assign more patients to better treatments as the trial moves 
along. An adaptive sample size estimation procedure can adjust the size of the trial 
according to the observed outcome. (v) The Bayesian method formally incorporates 
prior information gathered before, during, and outside of the trial. Clinical trials often 
do not arise from an information vacuum; however, standard trial designs do not allow 
researchers to take advantage of all the existing knowledge about the experimental 
agent(s). The Bayesian method allows researchers to incorporate information gathered 
before the trial in the prior distribution. A Bayesian framework also can incorporate 
the information accumulated in the trial and that acquired outside of the trial into 
the model for making inference. Bayesian meta-analysis provides a natural way to 
synthesize information across multiple trials. (vi) The Bayesian method can incorporate 
a utility function for informed decision making. Taking the Bayesian decision theoretic 
approach, clinical trial investigators can specify the “utility” or “loss” of various events. 
For example, “what is the utility (or importance) to the patient of being cured of cancer, 
and what is the loss to the patient if a long-term toxicity occurred due to the treatment?” 
The Bayesian method formulates the subjective preference for outcomes explicitly and 
quantitatively to aid investigators in making informed decisions. The optimal decision of 
the trial conduct can be made by maximizing the utility function or minimizing the loss 
function. However, Bayesian methods require the specification of the prior distribution, 
and the result may be sensitive to this choice. Bayesian methods are also more 
computationally intensive — a challenge that has been alleviated by the development of 
better computing algorithms and faster computers. Additional infrastructure is required 
for implementing Bayesian designs in clinical trials. Specialized software programs 
are often required for the study design, simulation, conduct, and analysis. Web-based 
applications are particularly useful for timely data entry, interim analysis, and reporting. 
Trial success requires not only the development of proper tools, but also timely and 
accurate execution of outcome evaluation, adaptive randomization, data analysis, and 
inference making. Bayesian methods hold great promise for improving the efficiency and 
flexibility of clinical trial conduct, and are ideal for learning and adaptation. Bayesian 
methods provide excellent tools for searching for effective treatments and predictive 
markers in the quest for biomarker-based personalized medicine — with a goal of 
treating more patients with more effective therapies both inside and outside the trial. 
Examples such as the BATTLE trial, the BATTLE-2 trial, and the I-SPY 2 trial will be 
illustrated. The relative merit of the Bayesian and frequentist approaches continues 
to be the subject of debate in statistics. Better statistical methods can lead to more 
efficient clinical trials designs, lower sample sizes, more accurate conclusions, and better 
outcomes for patients enrolled in the trials and beyond. The Bayesian approach offers an 
attractive alternative for better trials. More such trials should be designed and conducted 
and demonstrate its real benefit.
Keywords: inference making, trial efficiency and ethics, adaptive design, clinical trial 
conduct
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LUNG ADENOCARCINOMA, TISSUE CARCINOGENESIS    
Masayuki Noguchi  
Department Of Pathology, University Of Tsukuba, Tsukuba-shi/JAPAN
Pulmonary adenocarcinoma develops into invasive adenocarcinoma via atypical 
adenomatous hyperplasia (AAH), in situ adenocarcinoma (AIS), and minimally invasive 
adenocarcinoma (MIA) (1). AAH is a localized proliferation of mildly to moderately 
atypical cells lining involved alveoli and, sometimes, respiratory bronchioles. It is 
usually less than 5 mm in diameter and lacks any underlying interstitial inflammation 
or fibrosis. Previously, AAH was detected incidentally in the adjacent lung parenchyma 
in surgically resected specimens of lung adenocarcinoma, but recently it has become 
demonstrable by thin-slice CT scan examination, showing characteristic ground 
glass opacity (GGO), similarly to AIS. AAH shows positivity for TTF-1 antigen and 
is a preinvasive lesion of peripheral-type adenocarcinoma, especially the terminal 
respiratory unit (TRU) type (2). AAH is a preinvasive form of adenocarcinoma with 
an extrememly favorable prognosis. Adenocarcinoma with pure lepidic growth is a 
special subtype, because it mimics AAH. Among the pure lepidic adenocarcinomas, 
“adenocarcinoma in situ” is defined as localized small (<3 cm) adenocarcinoma showing 
growth that is restricted to neoplastic cells along preexisting alveolar structures (lepidic 
growth), and lacking stromal, vascular, or pleural invasion. Pathological differentiation 
between AAH and AIS is sometimes very difficult (3). AIS is classified as type A or B 
adenocarcinoma according to the 1995 Noguchi classification (4). AIS is usually non-
mucinous, but rarely it may be mucinous. MIA is a small, solitary adenocarcinoma 
(<3 cm) with a predominantly lepidic pattern and showing <5 mm invasion in greatest 
dimension at any one focus. By definition, the invasive component is composed of 
histological subtypes other than a lepidic pattern (i.e. acinar, papillary, micropapillary, 
and/or solid) or tumor cells infiltrating a myofibroblastic stroma (malignant stroma). 
MIA can be excluded if the tumor invades lymphatics, blood vessels, or the pleura, or 
contains tumor necrosis. If the tumor is larger than 2 cm, diagnosis should be made 
with caution, and the tumor needs to be extensively sampled, especially the solid 
component. On thin-slice CT examination, MIA demonstrates pure GGO or a partly 
solid appearance. On the basis of the modified Noguchi classification, MIA is classified 
as type C’ adenocarcinoma (3). The 5-year survival of patients with localized resected 
MIA is probably more than 95%. Invasive adenocarcinomas are classified on the 
basis of the predominant pattern after comprehensive histologic subtyping of lepidic, 
acinar, papillary, micropapillary, or solid patterns (5). Among the various subtypes, 
lepidic growth represents in situ growth or spreading of invasive adenocarcinoma, and 
the region showing lepidic growth does not influence outcome. Therefore, it is very 
important to assess the percentage of the lepidic subtype in invasive adenocarcinoma. 
References (1) Noguchi M. Stepwise progression of pulmonary adenocarcinoma. 
Clinical and molecular implications. Cancer Metastasis Rev 29:15-21, 2010. (2) Yatabe 
Y, Kosaka T, Takaashi T, et al. EGFR mutation is specific for terminal respiratory unit 
type adenocarcinoma. Am J Surg Pathol 29:633-9, 2005. (3) Minami Y, Matsuno Y, 
Iijima T, et al. Prognostication of small-sized primary pulmonary adenocarcinomas by 
histopathological and karyometric analysis. Lung Cancer 48:339-348, 2005. (4) Noguchi 
M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic 
characteristics and prognosis. Cancer 75:2844-2852, 1995. (5) Travis WD, Elisabeth B, 
Noguchi M, et al. International Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society International Multidisciplinary 
Classification of Lung Adenocarcinoma. J Thorac Oncol 6:244-285, 2011.
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MOLECULAR PATHOGENESIS OF LUNG ADENOCARCINOMA
Yasushi Yatabe  
Department Of Pathology And Molecular Diagnostics, Aichi Cancer Center, Nagoya/
JAPAN
Recent advances in lung cancer research have unveiled the molecular pathogenesis 
of lung cancer, especially in adenocarcinoma cases. Lung cancer has been shown to 
develop in a multistep fashion, thus genetic divergence can occur. In addition, genetic 
heterogeneity has been found within individual tumors by means of whole genome 
sequencing techniques. Such intra-tumor heterogeneity is greatly affected by the tumor 
evolution pattern, because early events take over the descendent and late events may 
cause heterogeneity due to divergence. As for lung adenocarcinoma, it is proposed that 
a precancerous lesion, namely atypical adenomatous hyperplasia (AAH), progresses to 
adenocarcinoma in situ (AIS), followed by invasive adenocarcinoma. Since the EGFR 
mutation has been found in AAH and AIS, it is considered to be acquired in the very 
early phase of lung adenocarcinoma development. We recently found that EGFR could 
be amplified in association with the EGFR mutation and that amplification was often 
heterogeneously distributed within individual tumors, with the amplified areas nearly 
exclusively seen in association with invasive growth by the tumor cells. Therefore, EGFR 
amplification is suggested to be involved in a transition step from AIS to invasive tumor. 
Interestingly, a mutated allele is selectively amplified in cases of amplification, and 
this was termed as mutated allele specific imbalance (MASI). Progression-associated 
EGFR gene amplification and MASI contribute to the pseudo-heterogeneity of the EGFR 
mutation, because mutated signals in an EGFR mutation test can be significantly over-
represented in the area with the gene amplification. Together, these findings show that 
EGFR is deeply involved in the progression of lung adenocarcinoma. In contrast, KRAS, 
a classic oncogene similar to EGFR, has a different effect on progression. KRAS mutations 
have been found in AAH, and some adenocarcinomas also have gene amplification in 
association with that mutation. However, the frequency of KRAS mutation declines along 
the proposed progression scheme, and KRAS amplification is quite rare even in tumors 
with the mutation. Furthermore, KRAS mutation is rather frequent in a different type 
of lung adenocarcinoma, i.e., invasive mucinous adenocarcinoma, the precursor lesion 
of which is unknown. Therefore, AAH could acquire either an EGFR or KRAS mutation, 
though the fate of the lesion may vary according to the mutation because of a different 
oncological impact. 
Keywords: lung adenocarcinoma, Molecular pathogenesis, EGFR, KRAS
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GENERAL LECTURE OF PATHOLOGY OF THYMOMA
Yoshihiro Matsuno, Yosuke Yamada, Utano Tomaru, Masanori Kasahara  
Hokkaido University, Sapporo/JAPAN
The pathologic classification of thymoma depends primarily on the findings of 
histomorphologic examination. As shown in many tumor types other than thymoma, 
a classification that is both biologically valid and clinically meaningful is required in 
order to provide a significant basis for advances in clinical oncology. Recently, a novel 
proteasome β subunit was found to be expressed exclusively in thymic cortical epithelial 
cells in both mice and humans. This subunit, designated β5t, is incorporated into 
thymoproteasomes, which are a specialized type of proteasome implicated in thymic 
positive selection. We performed immunohistochemical analysis of thymomas using an 
anti-β5t antibody, which detected β5t in the tumor epithelial cells. Among the subtypes 
of thymoma, β5t expression was observed in most cases of type B, but not in type A 
thymoma. Thus, as a marker of thymic cortical epithelial cells, β5t immunoreactivity can 
readily distinguish type A from type B thymoma. For the first time, this demonstration 
of the distribution of a functional molecule provided biological validation to the widely 
accepted morphology-based hypothesis that type B thymomas would be derived from 
cortical thymic epithelial cells, whereas type A thymomas are derived from medullary 
epithelial cells. Among the subtypes of thymoma, type AB thymoma, which comprises a 
type A component mixed with a type B component, shows a broad range of morphology 
despite being a single entity. However, the functional characteristics of the neoplastic 
cells responsible for this morphological variety remain to be clarified. We performed 
immunohistochemical analysis of type AB thymomas using anti-β5t and anti-TdT 
antibodies, and evaluated the various component tissue types, including type A-like, 
type B-like with spindle tumor cells, type B-like, and type B-like with medullary 
differentiation. The β5t-positivity ratio in each of these components was 5%, 20%, 42%, 
and 75%, respectively, and the corresponding mean ratios of TdT-positive lymphocytes 
were 9%, 59%, 75%, and 80%, respectively. Considering the distribution of β5t as a 
functional molecule of thymic cortical epithelial cells, together with morphologic 
features, it is suggested that type AB thymoma is not an entity distinct from either type 
A or type B thymoma, but in fact represents a spectrum of these subtypes with which it 
shares common features of natural history.
Keywords: thymoma, classification, proteasome, immunohistochemistry
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NEW ASPECTS OF THYMIC EPITHELIAL TUMORS
Alexander Marx1, Philipp Ströbel2  
1University Medical Center Mannheim, University Of Heidelberg, Mannheim/
GERMANY, 2University Medical Center Mannheim, University Of Heidelberg/
GERMANY
The WHO classification of thymic epithelial tumors has been criticized for poor inter-
observer reproducibility and some inconsistencies. Therefore, the International Thymic 
Malignancy Interest Group (ITMIG) organized conferences in 2011 in New York and 
Mannheim, Germany, gathering more than 20 expert pathologists, oncologists and 
surgeons from Asia, America and Europe, who concluded that the WHO classification 
should be maintained but needs improvement to better manage tumors with features 
intermediate between subtypes; tumors with atypia or high mitotic activity; tumors 
with more than one histological pattern. At the Mannheim slide workshop conventional 
and “borderland” cases were reviewed. H&E-based diagnoses were compared with 
consensus diagnoses that were achieved after disclosure of immuno-histochemical 
findings, discussion and voting. Consensus criteria and guidelines were formulated. 
Results Consensus: There was agreement between the H&E-based and consensus 
diagnoses in 85 % of cases. Discrepancies concerned “borderlands” between A and AB 
thymomas, B1 and B2 thymomas, and between B3 thymomas and thymic carcinomas. 
Immunohistochemistry (TdT) was mainly helpful at the A/AB-“borderland”. Spectrum 
of Type A and AB Thymoma A thymoma: Agreed-upon features are given in Table1 
for “conventional” A thymomas that were tentatively separated from rare “atypical 
A thymomas” (see below). In contrast to the WHO classification (2004), it was felt 
that lack of reticulin fibers (or collagen IV expression) does not reliably distinguish 
A from B3 thymomas. The new concept of “atypical A thymoma”: About 25% of A 
thymomas showed advanced tumor stage (demonstrating their malignant potential). 
Consensus criteria of atypia were increased mitotic activity and tumor necrosis. A 
recent paper by Nonaka and Rosai (AJSP, 2012) covers this topic. A versus AB thymoma: 
Immunohistochemistry showed that AB thymomas express cortical (e.g. PRSS16) and 
medullary markers (e.g. CD40; claudin 4), while A thymomas lack cortical markers. 
A thymomas should harbour no or few TdT+ T cells (“easy to count”) or a moderate 
amount of TdT+ T cells (“I could count if I had to”) in 10% or less of a given biopsie. A 
versus spindle cell B3 thymoma: Prominent and abundant perivascular spaces (PVS) 
strongly favor B3 thymoma, while abundant capillaries, rosettes, cysts, and epithelial 
CD20 expression favor type A thymoma. Table 1 Major (essential) and minor (optional) 
criteria of “conventional” A thymomas Major criteria: Spindly and/or polygonal-shaped 
tumor cells lacking atypia Paucity or absence of immature, TdT+ thymocytes (see text) 
Minor criteria: Occurrence of rosettes and/or subcapsular cysts Paucity or absence of 
PVS* contrasting with abundant capillaries Lack of Hassall’s corpuscles Complete or 
major encapsulation Encasement of individual tumor cells by reticulin fibers (Gomöri) 
Immunohistochemistry: Expression of CD20 in epithelial cells; absence of cortex-
specific markers; absence or paucity of TdT positive T cells  
____________________________________________________________ 
*Perivascular space Spectrum of B Thymomas There was consensus that the B1, B2 
and B3 division should be maintained even though these tumors apparently represent a 
continuum. B1 versus B2 thymomas: A “must” of B1 thymomas are “medulllary islands” 
that contain epithelial cells with or without Hassall’s corpuscles; a majority of TdT(-) 
T cells; and CD20(+) B-cells. Medullary islands optionally occur in B2 thymomas, and 
PVS and abundant TdT(+) T cells occur in B1 and B2 thymomas. The distinguishing 
features of B2 thymomas are increased numbers of epithelial cells compared to normal 
thymus, and epithelial cell clusters. B1 versus AB thymomas: AB and B1 thymomas can 
be lymphocyte-rich and can show medullary islands: However, Hassall’s corpuscles 
are absent in AB but present in 50% of B1 thymomas. The lymphocyte-rich areas in 
AB thymomas may mimic B1 thymomas; then, spindly tumor cells and epithelial 
CD20 expression identify AB thymomas (in 50%). B2 versus B3 thymoma: As a ‘rule 
of thumb’ H&E stained B2 and B3 thymomas give a “blue” and “pink” impression, 
respectively, due to the contrasting number of T cells. However, there are borderland 
cases that defy classification (to be illustrated). PVS and nuclear size are not helpful. 
Table 2 Major and minor features of B1 and B2 thymomas. NT, normal thymus Major 
criteria B1 Thymoma B2 Thymoma Impression at low power Thymus-like Heterogenous 
Confluence of epithelial cells No Yes Absence of type A areas Yes Yes Medullary islands 
Consistently + Optional Minor criteria Small lobular growth pattern Rare Common 
Large lobular growth pattern Common Rare Perivascular spaces Common Common 
Immunohistochem.: Keratin network Like in NT Denser than NT Distinguishing 
Thymoma from Thymic Carcinoma (TC) Borderland between B3 thymoma and 
Thymic Squamous Cell Carcinoma: B3 thymomas typically show lobular growth, 
conspicuous PVS, moderate atypia, lack of conspicuous intercellular bridges, presence 
of TdT(+) T-cells, and absent epithelial expression CD5, CD117 and Glut1. However, 
the following equivocal situations occur: Histologically typical B3 thymomas with 
expression of CD5 or CD117: There was consensus that CD5 and CD117 expressing 
epithelial cells in an otherwise typical B3 thymoma should entail a diagnosis of B3 
thymoma. Histologically typical B3 thymomas with lacking TdT+ T cells: There was 
consensus that lack of TdT(+) T cells in otherwise typical B3 thymomas should entail a 
diagnosis of B3 thymoma. Borderland between “thymoma with anaplasia” and TC: 
Focal anaplasia occurs in rare B2 and B3 thymomas. There was consensus that such 
tumors should be labelled as “B2 (or B3) thymoma with anaplasia”. Borderland between 
atypical A thymoma and (spindle cell) TC: Epithelial expression of CD20 is a potential 
marker of A thymomas. Unfortunately, expression of CD20 is often absent in “atypical” 
A thymomas. Whether CD5 and CD117 are useful here is unknown. New markers are 
needed at this borderland. “Combined Thymomas” There was consensus that this 
term should be abandoned to label thymomas composed of more than one histological 
type. Instead, diagoses for such thymomas should start with the most prevalent 
component followed by the second most prevalent etc. and give rough percentages of 
each component (in 10% increments) (“Gleason strategy”). By contrast, any thymic 
carcinoma component (irrespective of its proportion) should entail a diagnosis of 
“thymic carcinoma” complemented by a list of the thymoma component(s) and its/their 
percentage(s) (in 10% increments).
Keywords: thymoma, thymic carcinoma, ITMIG, immunohistochemistry
